Previous 10 | Next 10 |
FLORHAM PARK, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, will release financial re...
On the conclusion of the 2021 Russell indexes annual reconstitution, clinical-stage immunotherapy company PDS Biotechnology (PDSB) joined the Russell Microcap Index. Frank Bedu-Addo, President and CEO of PDS Biotech, commented, "Inclusion in the Russell Microcap Index underscores the pro...
FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, was added to the Russell Micro...
Mario13/E+ via Getty Images Intellia has a “more de-risked platform” now: Jefferies Intellia Therapeutics (NTLA) and Regeneron (REGN) have climbed sharply in the pre-market after the duo marked a milestone in CRISPR gene-editing with interim results for NTLA-2001 in transthyreti...
Gainers: Geron (GERN) +48%.CAI International (CAI) +46%.Sykes Enterprises (SYKE) +30%.PDS Biotechnology (PDSB) +18%.Smith & Wesson Brands (SWBI) +17%.Biophytis (BPTS) +13%.SemiLEDs (LEDS) +10%.Clean Energy Fuels (CLNE) +10%.Luokung Technology (LKCO) +10%.Vinco Ventures (BBIG) +9%.Los...
PDS Biotechnology (PDSB) announces the closing of its previously announced underwritten public offering of 6M shares at a price of $8.50/share for gross proceeds of about $51.7M.The company highlighted that the offering was inclusive of the 794K shares that were sold pursuant to the...
FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Company’s proprietary Versamune ® T-...
Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, Neu...
PDS Biotechnology (PDSB) slumps 27% premarket after pricing its public offering of 5,294,118 common shares at $8.50/share, for expected gross proceeds of ~$45M.Underwriters' over-allotment is an additional 794,117 shares. Net proceeds will be used for the development of clinical pip...
FLORHAM PARK, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...